Engineered immune cells take aim at two cancer targets
NCT ID NCT05437341
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study tests a new treatment called bi-specific CAR-T cells that target two proteins, PSMA and CD70, found on some cancer cells. The therapy involves taking a patient's own immune cells, engineering them to recognize and attack these proteins, and infusing them back. The trial aims to see if this approach is safe and effective for people with advanced cancers that have not responded to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bi-4SCAR PSMA/CD70 T cells
What this could lead to
If successful, this could provide a new treatment option for patients with certain advanced cancers that express PSMA or CD70.
What could go wrong
This is an early-phase trial (phase 1/2) with only 60 participants, so safety and effectiveness are not yet proven. CAR-T therapy can cause severe side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.